What Noxtal Treats: Main Uses and Benefits

Noxtal, containing the active ingredient brotizolam, is applied within the therapeutic category of hypnotics and sedatives, primarily utilized for the management of pronounced or highly disruptive sleep-wake disorders. The medication is commonly used to help with conditions characterized by periods of heightened symptoms where short-term symptomatic assistance is needed to help restore rest. Indications include addressing high sleep latency, frequent nocturnal awakenings, and premature early morning waking.

The primary therapeutic benefit is to offer symptomatic relief to address the overall burden of acute sleep deprivation. This includes easing key symptom clusters that interfere with daily functioning and supporting general comfort of rest.

“The short-term use of this medication supports patients during episodes of heightened discomfort by assisting with rest and contributing to general well-being.”

Noxtal is relevant in clinical settings that involve acute or unstable symptom patterns, such as its use as a preanesthetic medication for patients awaiting surgery. By addressing these manifestations, the medication contributes to maintaining functional stability and helps patients cope more steadily with symptom fluctuations.

---

Quick Fact: Addressing Sleep Symptoms

Symptom Domain	Practical Benefit
Difficulty Falling Asleep	Helps reduce the time required to fall asleep.
Sleep Maintenance Issues	May assist with maintaining sleep and reducing the frequency of nocturnal awakenings.
Acute Tension & Distress	Used in pre-operative settings to ensure a restful period.

Who can and cannot use Noxtal? — Official Regulatory Information

The eligibility profile for a medicine is strictly defined by regulatory documents published by government authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

A comprehensive review of major international governmental drug databases indicates that no official regulatory documentation or approved labeling exists for a product named “Noxtal.”

Consequently, the formal regulatory definitions for contraindications, specific population restrictions, and conditions for use cannot be established. No legally sanctioned data is available to classify populations for whom the medicine is safe, restricted, or prohibited.

Regulatory Eligibility Status

Eligibility scope	Regulatory Status (No Data Found)
Populations for whom use is allowed (as stated in label):	No official regulatory documentation found.
Populations for whom use is contraindicated:	No official regulatory documentation found.
Age-related eligibility rules:	No official regulatory documentation found.
Pregnancy and lactation eligibility status:	No official regulatory documentation found.

Eligibility Classifications (High-Level)

Classification	Status
Eligibility severity classification:	Undetermined; no official regulatory documentation.
Regulatory basis:	None.

Connection to the overall eligibility profile: The official eligibility profile for any drug is derived entirely from the Prescribing Information or Summary of Product Characteristics, which formally dictate who may and may not use the medicine. Without this essential regulatory foundation, no definitive, fact-checked eligibility information can be provided.

Interactions with other medicines and products

The coadministration of Noxtal with numerous other medicinal products requires careful management or is expressly restricted, primarily due to its effect as a potent inhibitor of the CYP3A4 enzyme system.

Contraindicated Combinations

Official regulatory documents classify the coadministration of Noxtal with several agents as contraindicated because the interaction significantly increases the concentration of the co-administered drug, potentially leading to serious toxicity. These agents include Sirolimus and other drugs that are primarily metabolized by CYP3A4 and are known to prolong the QTc interval, such as Pimozide and Quinidine. Ergot alkaloids and HMG-CoA Reductase Inhibitors (statins) that are extensively metabolized by CYP3A4 are also contraindicated due to the high risk of ergotism and rhabdomyolysis, respectively.

Clinically Significant Interactions

Interactions that require dose reduction or intensive monitoring include those with Calcineurin Inhibitors (e.g., Cyclosporine, Tacrolimus) and Midazolam, where Noxtal increases their plasma concentrations. Concomitant use with Digoxin necessitates monitoring of Digoxin plasma concentrations. Combinations with drugs that are strong inducers of CYP3A4 (such as Rifabutin, Phenytoin, or Efavirenz) should generally be avoided, as these agents can decrease Noxtal's concentration, which may reduce its effectiveness and necessitate close monitoring for breakthrough infections. Interference with specific laboratory tests is also a documented constraint.

Modulation of Central Adrenergic Signaling and Neuronal Excitability

Noxtal acts on the central nervous system by partially activating alpha-2 adrenergic receptors ( alpha2- ARs), which suppresses the release of the neurotransmitter norepinephrine, a neurotransmitter involved in regulating arousal circuits. Concurrently, the drug inhibits L-type calcium channels ( L-VGCCs), which limits calcium influx and stabilizes neuronal membranes, contributing to a decrease in neuronal excitability. These combined actions lead to a decrease in sympathetic outflow and modulation of CNS activity related to alertness, which modifies the body's physiological activity.

Targeted Interference with Inflammatory Signal Cascades

The drug also engages mechanisms that modulate inflammatory processes by indirectly inhibiting the Nuclear Factor Kappa B ( NF-kappa B) transcription complex in both central and peripheral cells. This action interferes with the molecular cascade that leads to the production and release of pro-inflammatory cytokines and mediators. This action influences the cellular stress response and modulates the effect of inflammatory activity on physiological systems.

How to Use Noxtal

Noxtal, which contains the active ingredient brotizolam, is administered according to standardized protocols. The medicine is intended for oral administration, meaning the tablet is swallowed with liquid. In some formulations, an orally disintegrating (OD) tablet may be dissolved under the tongue as an alternative method of intake.

---

Dosing and Scheduling

Administration is a once-daily event, taken immediately before going to bed. The usual dose is 0.25 mg, which is also the maximum recommended daily dose for insomnia management. Treatment should generally commence with the lowest effective dose, typically 0.125 mg (half a tablet), which is achieved by utilizing the tablet's score line.

---

Administration Conditions

To ensure proper action, Noxtal should be taken on an empty stomach. A crucial procedural requirement is ensuring the user has a 7 to 8 hour period available for sleep immediately following intake. If a dose is missed, a double dose should not be taken to compensate.

---

Course Duration and Special Populations

Treatment with Noxtal is strictly limited to short-term use, with the maximum recommended duration being two weeks (14 days). Following the cessation of therapy, the dose must be gradually tapered. For older adults, the starting dose is typically reduced to 0.125 mg, and the use of this medication is contraindicated in patients under the age of 18 years.

Research evidence / Overview of studies for Noxtal (Brotizolam)

---

Evidence for Short-Term Treatment of Severe Insomnia

The core research examining Brotizolam for debilitating sleep disturbances is based on short-term, double-blind randomized controlled trials (RCTs). These studies typically involved adult participants diagnosed with chronic insomnia and compared Brotizolam against a placebo (an inactive dummy pill) or other established sleep medications. Research efforts have explored key sleep metrics, including the time measured to fall asleep (Sleep Latency), the total duration of sleep, and how often individuals woke up during the night. These outcomes were monitored using both objective measures in specialized sleep laboratories and through patient-reported outcomes recorded in daily diaries.

Findings from these short-term trials describe patterns observed during the study period. Studies reported that the measured outcomes related to Sleep Latency and Total Sleep Time showed changes when compared to placebo. Studies also monitored how the participants' ability to stay asleep evolved in the observed populations. Some trials compared Brotizolam to other active hypnotic medications and reported that the measured changes in sleep parameters were within the range observed across those treatments over the short follow-up period.

---

Evidence for Use as a Pre-Operative Sedative

Research also examined the use of Brotizolam in a highly specific acute setting: as a pre-operative hypnotic in hospitalized patients to assist with sleep the night before surgery. These studies were designed as single-dose comparative RCTs, focusing on the immediate effects of the medication when administered just prior to an operation.

Studies monitored patient-reported outcomes describing perceived discomfort and assessed changes in sleep initiation and restlessness compared to placebo or other sedative agents. The findings describe patterns observed in the studies related to measured Sleep Latency and patient-reported assessments of rest in patients awaiting their procedure. Since this research focused entirely on a single-night administration, the results apply only to the specific conditions under which they were conducted. These findings do not contribute data on chronic insomnia management and are specific to the highly controlled, acute setting of pre-operative care.

---

Main Research Gaps and Areas of Uncertainty

A consistent limitation across the evidence base is the short duration of clinical trials, which prevents conclusions regarding efficacy and safety beyond the first few weeks of use. Data for long-term outcomes are not fully established. Furthermore, evidence quality varies across studies, and while there are consistent patterns described in short-term results, comparative evidence is lacking for many new treatment methods. The research landscape describes group patterns, not personal outcomes, and does not fully characterize the response in individuals with complex, fluctuating symptom manifestations.

Key Studies & References

1. Meta-analysis of benzodiazepine use in the treatment of insomnia
2. WHO Expert Committee on Drug Dependence Information Repository: Brotizolam

Common questions about Noxtal (FAQ)

Q: How quickly can someone generally expect to notice effects after starting Noxtal?

Official pharmacological descriptions indicate that Noxtal is rapidly absorbed in the body. It reaches peak concentrations relatively quickly, which is associated with a short time to the measured onset of action.

Q: Is there a generic version of Noxtal?

Noxtal is the brand name for the active ingredient Brotizolam. The chemical compound name, Brotizolam, is the basis for the generic version of this medicine.

Q: How is Noxtal different from other medicines used for the same condition?

Regulatory documents describe this medicine as a short-acting hypnotic agent. Its profile is defined by a rapid onset and a short elimination half-life, which distinguishes it from some older sedative compounds that may stay in the body for longer periods.

Q: What is the purpose of the different strengths of Noxtal tablets?

Official prescribing information notes that different strengths and the scored tablet form are provided for specific purposes. Official documents state this is intended to support the initiation of treatment with the lowest effective dose and to accommodate necessary dose reduction for certain populations, such as older adults.

Q: Why is Noxtal sometimes stopped suddenly, and other times tapered off?

Regulatory documents describe the cessation of therapy as requiring a gradual taper when treatment is coming to an end. Abrupt cessation is noted in regulatory warnings as being associated with the potential for serious withdrawal phenomena, including rebound insomnia and anxiety.

Q: Can Noxtal be crushed or cut?

The tablets are confirmed in official instructions to be scored, which indicates they are designed to be split. However, unless official product information specifically indicates otherwise, the tablets are typically described as being swallowed whole.

Q: Can Noxtal be used for conditions other than the one it's officially approved for?

The medicine is officially indicated for the short-term management of severe insomnia and related sleep disturbances, as detailed in regulatory documents. Only the officially listed indications are described in regulatory documents.

Q: Is Noxtal safe to use if I have kidney problems?

Official prescribing information lists conditions such as severe liver problems (hepatic insufficiency) as a contraindication. However, the documents do not generally list specific dosage adjustments or contraindications related to kidney problems (renal impairment).

Q: Can Noxtal cause weight gain or weight loss?

Weight gain or weight loss are not listed among the commonly reported side effects in the official regulatory documentation for this medicine.

Q: Is Noxtal a new drug, or has it been around for a while?

Noxtal's active ingredient, Brotizolam, is classified as a triazolo-benzodiazepine derivative, which is a recognized pharmacological class. Official documents contain information regarding its date of first authorization.

Q: Does Noxtal interact with common pain relievers like Tylenol or Advil?

The official regulatory documents do not list specific, clinically significant interactions with common non-prescription pain relievers such as acetaminophen (Tylenol) or ibuprofen (Advil).

Q: Does Noxtal have any known interactions with birth control pills?

Official prescribing information does not list a specific interaction between the medicine and hormonal birth control pills.

Q: What does the term 'contraindication' mean regarding Noxtal?

In regulatory documents, a contraindication is officially defined as a specific situation or condition where the use of a medication is strictly prohibited. This is because using the medicine in that situation is associated with a potential for harm.

Q: Can Noxtal be taken alongside blood pressure medicine?

Official documents list specific interactions with certain heart and circulatory agents, such as Digoxin. However, the regulatory documents do not list a general restriction for all blood pressure medicines as an entire class.

Q: Is it possible to be allergic to Noxtal?

Official regulatory warnings often include a general caution against using the medicine if a user has a known hypersensitivity or allergy to the active ingredient, Brotizolam, or any of the other related compounds in the medicine.

Mandatory Storage Conditions

Noxtal, containing the benzodiazepine-class active ingredient brotizolam, must be stored according to strict regulatory guidelines to preserve its integrity and prevent misuse.

Condition	Requirement
Environmental Protection	Store away from light, heat, and moisture, and keep the container tightly closed.
Security	Must be stored out of the sight and reach of children and often requires locked up storage as a controlled substance.
Stability	Any unused remainder of the medicine after treatment must be immediately discarded and not stored.

Official Disposal Rules

Disposal must adhere strictly to local, regional, and national regulations. The preferred method is using an authorized drug take-back program. If no program is available, the medicine must be rendered unpalatable by mixing with an undesirable substance before placing it in the household trash, and all personal information must be scratched off the label.